Organogenesis Holdings Inc. insider trading
Every open-market purchase and sale by Organogenesis Holdings Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Organogenesis Holdings Inc.’s insiders pay?
From September 5, 2019 to March 11, 2026, 20 insiders reported 36 open-market purchases and 20 sales not made under a pre-set plan in Organogenesis Holdings Inc. Twelve months after each purchase was reported, the shares were −14.5% against the S&P 500 on average (median −39.1%), over 28 purchases with a full year of prices; 29% beat the index. After sales, the shares moved −59.7% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on September 6, 2019 into $6,948 by November 2, 2026, −5.0% a year. It held shares 52% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $17,507 (+8.2% a year), and held throughout $28,181 (+15.6%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Katz Michael W | 10% owner | 9 | −39.8% (8) | 13% | 0 | — | November 22, 2022 |
| Nussdorf Glenn H | Director | 3 | −41.1% (2) | 0% | 3 | — | December 18, 2025 |
| Mackie Wayne D | Director | 5 | −1.8% (5) | 40% | 0 | — | December 3, 2020 |
| Gn 2016 Family Trust U/a/d August 12, 2016 | Director | 1 | +66.8% (1) | 100% | 3 | −66.0% (2) | April 14, 2023 |
| Leibowitz Arthur S | Director | 4 | +13.8% (2) | 50% | 0 | — | March 11, 2026 |
| Wisdom Starr | Director | 1 | +66.8% (1) | 100% | 3 | −62.6% (3) | May 28, 2021 |
| Albert Erani Family Trust Dated 12/29/2012 | Director | 2 | −49.6% (2) | 0% | 1 | −29.3% (1) | June 8, 2022 |
| Driscoll Michael Joseph | Director | 2 | — | — | 1 | −66.4% (1) | March 11, 2026 |
| Gillheeney Gary S. | President and CEO | 0 | — | — | 3 | — | December 16, 2024 |
| Avista Acquisition Corp. | Director | 2 | −43.0% (1) | 0% | 0 | — | March 16, 2020 |
| Avista Capital Partners IV, L.P. | Director | 2 | +24.5% (2) | 50% | 0 | — | November 24, 2020 |
| Dennis Erani 2012 Issue Trust Dated 12/20/12 | Director | 0 | — | — | 2 | — | January 11, 2024 |
| Erani Dennis | 10% owner | 1 | −43.0% (1) | 0% | 1 | −61.2% (1) | June 28, 2021 |
| Avista Acquisition, LLC | Director | 1 | −47.9% (1) | 0% | 0 | — | September 13, 2019 |
| Avista Capital Managing Member IV, LLC | Director | 1 | −39.1% (1) | 0% | 0 | — | September 5, 2019 |
| Dean Thompson | Director | 1 | +66.8% (1) | 100% | 0 | — | November 19, 2020 |
| Freedman Lori | Chief Admin. and Legal Officer | 1 | — | — | 0 | — | June 6, 2025 |
| Gn 2016 Organo 10-Year Grat U/a/d September 30, 2016 | Director | 0 | — | — | 1 | −59.7% (1) | June 10, 2021 |
| Montecalvo Antonio S. | Vice President, Health Policy | 0 | — | — | 1 | −65.3% (1) | March 11, 2022 |
| Organo Pfg LLC | Director | 0 | — | — | 1 | −55.2% (1) | February 16, 2021 |
When several insiders traded Organogenesis Holdings Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Organogenesis Holdings Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged +42.4% against the index. After 1 selling crowd, −57.0%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| November 30, 2021 | 3 buying | −9.1% | −35.8% | −63.6% |
| June 30, 2021 | 4 selling | −13.1% | −57.0% | −60.0% |
| November 30, 2020 | 7 buying | +193.6% | +201.7% | +67.7% |
| September 30, 2019 | 9 buying | −35.1% | −38.6% | −55.1% |